NASDAQ:NCNA - NuCana Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NuCana PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.25 -0.64 (-8.11 %) (As of 12/13/2019 04:00 PM ET) Add Compare Today's Range$7.06Now: $7.25▼$8.1150-Day Range$5.52MA: $7.10▼$8.4852-Week Range$4.01Now: $7.25▼$19.28Volume107,455 shsAverage Volume56,625 shsMarket Capitalization$233.89 millionP/E RatioN/ADividend YieldN/ABeta3.18 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NCNA Previous Symbol CUSIPN/A CIK1709626 Webhttp://www.nucana.com/ Phone44-0-13-1357-1111Debt Debt-to-Equity RatioN/A Current Ratio13.05 Quick Ratio13.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book2.12Profitability EPS (Most Recent Fiscal Year)($0.57) Net Income$-18,470,000.00 Net MarginsN/A Return on Equity-22.77% Return on Assets-21.10%Miscellaneous Employees21 Outstanding Shares32,260,000Market Cap$233.89 million Next Earnings Date3/5/2020 (Estimated) OptionableNot Optionable Receive NCNA News and Ratings via Email Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NCNA Rates by TradingView NuCana (NASDAQ:NCNA) Frequently Asked Questions What is NuCana's stock symbol? NuCana trades on the NASDAQ under the ticker symbol "NCNA." How were NuCana's earnings last quarter? NuCana PLC (NASDAQ:NCNA) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($12.00) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($22.80) by $10.80. View NuCana's Earnings History. When is NuCana's next earnings date? NuCana is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for NuCana. What price target have analysts set for NCNA? 5 brokerages have issued 1 year price objectives for NuCana's stock. Their forecasts range from $15.00 to $25.00. On average, they expect NuCana's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 162.1% from the stock's current price. View Analyst Price Targets for NuCana. What is the consensus analysts' recommendation for NuCana? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuCana. What are Wall Street analysts saying about NuCana stock? Here are some recent quotes from research analysts about NuCana stock: 1. According to Zacks Investment Research, "NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. " (11/20/2019) 2. HC Wainwright analysts commented, "We have valued NuCana on a discounted cash flow (DCF) basis, which yields a $624M projected enterprise value as of mid-2020. Our calculations rely upon a 60% probability of approval for Acelarin across both front-line BTC and fourth-line 30% probability of approval for NUC-3373 in the mCRC indication. We utilize a 12% discount rate and 17% effective corporate income tax rate, along with a 1% terminal growth rate." (8/19/2019) Has NuCana been receiving favorable news coverage? News stories about NCNA stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NuCana earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for NuCana. Who are some of NuCana's key competitors? Some companies that are related to NuCana include Amphastar Pharmaceuticals (AMPH), TG Therapeutics (TGTX), Vanda Pharmaceuticals (VNDA), Homology Medicines (FIXX), ZIOPHARM Oncology (ZIOP), G1 Therapeutics (GTHX), Achillion Pharmaceuticals (ACHN), Dova Pharmaceuticals (DOVA), IGM Biosciences (IGMS), Eagle Pharmaceuticals (EGRX), XBiotech (XBIT), Flexion Therapeutics (FLXN), CannTrust (CNTTF), Stoke Therapeutics (STOK) and Aprea Therapeutics (APRE). What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), Tetraphase Pharmaceuticals (TTPH), Protalix Biotherapeutics (PLX), Achaogen (AKAO), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), Allena Pharmaceuticals (ALNA), Uniqure (QURE), Rigel Pharmaceuticals (RIGL) and VBI Vaccines (VBIV). Who are NuCana's key executives? NuCana's management team includes the folowing people: Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 73)Mr. Hugh S. Griffith, Founder, CEO & Director (Age 51)Mr. Donald Munoz, Chief Financial Officer (Age 50) When did NuCana IPO? (NCNA) raised $100 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager. Who are NuCana's major shareholders? NuCana's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wildcat Capital Management LLC (1.64%), Tang Capital Management LLC (1.55%), Endurant Capital Management LP (1.19%), Millennium Management LLC (0.50%) and Rothschild Investment Corp IL (0.08%). Which major investors are selling NuCana stock? NCNA stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL. Which major investors are buying NuCana stock? NCNA stock was acquired by a variety of institutional investors in the last quarter, including Wildcat Capital Management LLC, Tang Capital Management LLC, Endurant Capital Management LP and Millennium Management LLC. How do I buy shares of NuCana? Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is NuCana's stock price today? One share of NCNA stock can currently be purchased for approximately $7.25. How big of a company is NuCana? NuCana has a market capitalization of $233.89 million. The company earns $-18,470,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. NuCana employs 21 workers across the globe.View Additional Information About NuCana. What is NuCana's official website? The official website for NuCana is http://www.nucana.com/. How can I contact NuCana? NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected] MarketBeat Community Rating for NuCana (NASDAQ NCNA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 201 (Vote Outperform)Underperform Votes: 188 (Vote Underperform)Total Votes: 389MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2019 by MarketBeat.com StaffFeatured Article: How much money do you need to begin day trading?
